<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250921</date><key>collection.key</key><document><id>5771473</id><infon key="license">author_manuscript</infon><passage><infon key="article-id_doi">10.1530/JOE-17-0524</infon><infon key="article-id_manuscript">NIHMS925100</infon><infon key="article-id_pmc">5771473</infon><infon key="article-id_pmid">29191939</infon><infon key="fpage">57</infon><infon key="issue">2</infon><infon key="kwd">bone formation and resorption cartilage histology ob/ob osteoclast</infon><infon key="license">
          This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
        </infon><infon key="lpage">68</infon><infon key="name_0">surname:Philbrick;given-names:Kenneth A.</infon><infon key="name_1">surname:Martin;given-names:Stephen A.</infon><infon key="name_2">surname:Colagiovanni;given-names:Amy R.</infon><infon key="name_3">surname:Branscum;given-names:Adam J.</infon><infon key="name_4">surname:Turner;given-names:Russell T.</infon><infon key="name_5">surname:Iwaniec;given-names:Urszula T.</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">236</infon><infon key="year">2019</infon><offset>0</offset><text>Effects of hypothalamic leptin gene therapy on osteopetrosis in leptin-deficient mice</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>86</offset><text>Impaired resorption of cartilage matrix deposited during endochondral ossification is a defining feature of juvenile osteopetrosis. Growing, leptin-deficient ob/ob mice exhibit a mild form of osteopetrosis. However, the extent to which the disease is (1) self-limiting and (2) reversible by leptin treatment is unknown. We addressed the first question by performing histomorphometric analysis of femurs in rapidly growing (2-month-old), slowly growing (4-month-old), and skeletally mature (6-month-old) wild type (WT) and ob/ob male mice. Absent by 6 months of age in WT mice, cartilage matrix persisted to varying extents in distal femur epiphysis, metaphysis and diaphysis in ob/ob mice, suggesting that the osteopetrotic phenotype is not entirely self-limiting. To address the second question, we employed hypothalamic recombinant adeno-associated virus (rAAV) gene therapy to restore leptin signaling in ob/ob mice. Two-month-old mice were randomized to one of three groups: (1) untreated control, (2) rAAV-Leptin, or (3) control vector rAAV-green fluorescent protein and vectors injected intracerebroventricularly. Seven months later, rAAV-Leptin-treated mice exhibited no cartilage in the metaphysis and greatly reduced cartilage in the epiphysis and diaphysis. At the cellular level, the reduction in cartilage was associated with increased bone turnover. These findings (1) support the concept that leptin is important for normal replacement of cartilage by bone, and (2) demonstrate that osteopetrosis in ob/ob mice is bone compartment specific and reversible by leptin at skeletal sites capable of undergoing robust bone turnover.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1727</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1740</offset><text>The appetite regulatory hormone leptin is produced by adipose tissue, circulates in levels proportional to total adiposity, and may act to couple skeletal metabolism to energy availability. Long bones in leptin-deficient ob/ob mice are shorter, biomechanically weaker, and exhibit lower overall bone mass and greater marrow adiposity compared to wild type (WT) mice. However, differences in cancellous bone volume fraction between ob/ob and WT mice vary depending upon skeletal site and age. Leptin treatment in leptin-deficient mice normalizes bone volume and microarchitecture by increasing bone formation and resorption, and increasing longitudinal bone growth. Leptin treatment also normalizes bone marrow adiposity by reducing marrow adipocyte number and size. Taken together, these findings indicate that leptin affects bone marrow adiposity and skeletal growth, maturation, and turnover balance.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2643</offset><text>Calcified cartilage provides a structural template for growing long bones during endochondral ossification and is normally replaced by bone during skeletal maturation. However, long bones of leptin-deficient ob/ob mice retain cartilage within cortical and cancellous bone compartments into adulthood resulting in a mild osteopetrotic skeletal phenotype. Osteopetrosis is broadly characterized into two major subtypes, osteoclast-poor and osteoclast-rich. Mutations and/or factors that inhibit osteoclast formation are responsible for osteoclast-poor osteopetrosis. In contrast, mutations or factors that reduce osteoclast activity but do not inhibit osteoclast formation are responsible for the osteoclast-rich form of the disease. Both forms of osteopetrosis result in reduced bone resorption. Severe osteopetrosis is fatal while mild forms, such as that noted in ob/ob mice, result in decreased bone quality. Furthermore, some forms of osteopetrosis are self-limiting; abnormally high quantities of cartilage are initially present in bone during rapid growth but the cartilage is eventually replaced as skeletal growth slows with age. At present, it is unclear whether the mild osteopetrosis observed in growing ob/ob mice is self-limiting.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3886</offset><text>Osteoclast perimeter in ob/ob mice is equal to or greater than in WT mice. In contrast, serum levels of carboxy-terminal collagen crosslinks (CTx, a biochemical marker of global bone resorption) are generally much lower and fluorochrome label retention in bone (a histomorphometric index of local bone resorption) is higher in ob/ob mice compared to WT mice, providing strong complementary evidence that leptin deficiency results in reduced bone resorption. Theoretically, excessive bone formation could contribute to mild osteopetrosis. However, bone formation is impaired by leptin deficiency, indicating that lower osteoclastic activity is responsible for the condition in ob/ob mice.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4574</offset><text>Osteoclast-rich forms of osteopetrosis can be induced by loss of function mutations in genes coding for proteins such as protease cathepsin K or chloride transporter ClCN7 required for osteoclastic activity but not for osteoclast formation and survival. Additionally, drugs that inhibit bone resorption, such as bisphosphonates, have been shown to induce osteoclast-rich osteopetrosis in children. The mechanism for leptin regulation of osteoclast activity has yet to be established but likely involves coordinated actions of the hormone on multiple genes that in concert regulate osteoclast activity. In support, gene profiling has established that leptin deficiency results in altered expression of several genes related to osteoclast differentiation and function.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5341</offset><text>In the present investigation, we queried the extent to which osteopetrosis in ob/ob mice is (1) self-limiting and (2) reversible by leptin treatment. We addressed the first question by performing histomorphometric analysis of femurs in rapidly growing (2-month-old), slowly growing (4-month-old), and skeletally mature (6-month-old) WT and ob/ob male mice. To address the second question, we employed hypothalamic recombinant adeno-associated virus (rAAV) gene therapy in 2-month-old ob/ob mice to restore leptin signaling and evaluated the bone response 7 months later. rAAV gene therapy has been used as an experimental strategy for life-long restoration of leptin signaling in leptin-deficient ob/ob mice.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>6050</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6072</offset><text>Animals</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6080</offset><text>Male C57BL/6J (B6) mice and ob/ob mice on a B6 genetic background were obtained from Jackson Laboratory (Bar Harbor, Maine). Mice were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the experimental protocols were approved by the Institutional Animal Care and Use Committee. Mice were housed individually in a temperature (22°C) and light-controlled (lights on 6am – 6pm) room. Food (standard mouse chow) and water were available ad libitum to all animals.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6584</offset><text>Study 1: Effects of Age and Leptin Status on Bone and Cartilage in Femur</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6657</offset><text>Study 1 was performed in WT and ob/ob mice to determine the distribution of cartilage in femurs in animals sacrificed at 2 (n=10/group), 4 (n=5/group), and 6 (n=3-5/group) months of age. Two-month-old mice are rapidly growing while skeletal maturity is reached between 4 and 6 months of age.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6949</offset><text>Study 2: Effect of Hypothalamic Leptin Gene Therapy on Bone and Cartilage in ob/ob Mice</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7037</offset><text>Study 2 was performed in ob/ob mice to determine if the osteopetrotic skeletal phenotype persists in aged mice and, if so, whether long-duration hypothalamic leptin gene therapy normalizes skeletal maturation. Two-month-old ob/ob mice were randomized into one of three treatment groups: (1) untreated control (n=7), (2) rAAV-Leptin (rAAV-Lep, n=9), or rAAV-GFP (control vector encoding green fluorescent protein, n=7). The mice were maintained for 7 months post-vector administration. The effects of treatment on hypothalamic leptin gene expression, food intake, body weight, circulating metabolic hormone levels, bone microarchitecture, and bone marrow adiposity have been reported elsewhere.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>7731</offset><text>Construction and packaging of recombinant adenovirus vectors (rAAV)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7799</offset><text>rAAV-Lep and rAAV-GFP vectors were constructed and packaged as described. In brief, the vector pTR-CBA-Ob EcoRI fragment of pCR-rOb containing rat leptin cDNA was subcloned into rAAV vector plasmid pAAVβGEnh after deleting the EcoRI fragment carrying the β-glucoronidase cDNA sequence. The control vector, rAAV-GFP, was similarly constructed to encode the GFP gene.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8171</offset><text>Vector administration</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8193</offset><text>For vector administration, the mice were anesthetized with sodium pentobarbital (60 mg/kg, ip), placed on a Kopf stereotaxic apparatus with mouse adapter for intracerebroventricular (icv) injection, and injected icv with either rAAV-Lep (9 × 107 particles) or rAAV-GFP (9 × 107 particles). This dose was shown to normalize body weight in ob/ob mice. The coordinates employed for microinjector placement in the 3rd cerebroventricle were 0.3 mm posterior to bregma, 0.0 lateral to midline, and 4.2 mm below the dura.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8710</offset><text>Tissue collection and analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8741</offset><text>Mice were anesthetized with either isoflurane delivered in oxygen (Study 1) or sodium pentobarbital (60 mg/kg; ip) (Study 2) and killed by exsanguination. Femora were excised, cleaned of soft tissue, placed in 10% formalin for 24 hrs, and stored in 70% ethanol until processing. Distal femora were prepared for histomorphometric evaluation as described. In brief, undecalcified femora were dehydrated and embedded in modified methyl methacrylate. Frontal sections, 4 μm thick, were cut with a vertical bed microtome (Leica 2065) and affixed to gel-coated slides. One slide was stained for tartrate resistant acid phosphatase and counter stained with toluidine blue (pH 2.5) to identify osteoclasts and cartilage matrix, respectively. Cartilage matrix was identified by metachromatic staining of proteoglycans and glycosaminoglycans. A second slide was stained using the Von Kossa method and counter stained with tetrachrome to identify osteoblasts and verify that linear growth had ceased in the femur in 6-month-old mice: the presence of bone bridging across the growth plate was used as an index of termination of longitudinal bone growth. Cartilage was measured in cancellous bone in the distal femur epiphysis and metaphysis and in cortical bone in the femoral diaphysis. The entire cancellous envelope was evaluated in the distal femur epiphysis. The region of interest in the distal femur metaphysis was located 0.25-0.85 mm proximal to the growth plate and 0.05 mm from cortical bone. Cortical bone was evaluated 4.4-5.6 mm proximal to the growth plate. Measurements of cartilage included metachromatic stained area and chondrocyte area in the epiphysis, metaphysis, and diaphysis. Measurements excluded growth plate and articular cartilage matrix. Osteoclast perimeter (osteoclast perimeter/bone perimeter, %) and osteoblast perimeter (osteoblast perimeter/bone perimeter, %) were also determined in the epiphysis. Measurements were done at either 20 or 40x using the Osteomeasure Histomorphometry System (Osteometrics, Atlanta, GA). Histomorphometric data are reported using standard 2-dimensional nomenclature.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>10863</offset><text>Statistics</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10874</offset><text>Mean responses for bone and cartilage area fraction were compared between WT and ob/ob mice at ages 2 months, 4 months, and 6 months using analysis of covariance (age modeled as a quantitative variable with linear structure) or two-way analysis of variance (age modeled as a categorical variable). Goodness of fit assessment from scatterplots, Levene’s test for homogeneity of variance, plots of residuals versus fitted values, normal quantile plots, and Anderson-Darling tests of normality, and model selection from Akaike’s information criterion, Bayesian information criterion, and likelihood ratio tests were used to determine a linear model and evaluate contributions from interactions and main effects. Linear models containing different variance parameters across age and/or genotype groups were used to accommodate heterogeneous variance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11725</offset><text>Mean responses for bone and cartilage fraction, and osteoblast and osteoclast perimeter were compared between the ob/ob, ob/ob + rAAV-GFP, and ob/ob + rAAV-Lep groups using one-way analysis of variance, with t-tests used to make pairwise comparisons. The Kruskal-Wallis nonparametric test was used when only the normality assumption was violated, in which case the Wilcoxon-Mann-Whitney test was used for two-group comparisons. A modified F test was used when variances were distinct, with Welch’s two-sample t-test used for two-group comparisons.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12275</offset><text>The Benjamini and Hochberg method for maintaining the false discovery rate at 5% was used to adjust for multiple comparisons. Differences were considered significant at p ≤ 0.05. Trends are reported when P &lt; 0.1. All data are presented as mean ± SE. Data analysis was performed using R version 3.2.2.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>12579</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12587</offset><text>Study 1: Effects of Age and Leptin Status on Bone and Cartilage in Femur</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12660</offset><text>The effects of age and leptin status on cancellous bone area fraction in the femoral epiphysis and metaphysis and on cartilage retention in the femoral epiphysis, metaphysis, and diaphysis in WT and ob/ob mice are shown in Figure 1. Cancellous bone area fraction decreased with age in epiphysis (Figure 1A) and metaphysis (Figure 1C). The rate of decrease was not affected by genotype (interaction not significant). However, cancellous bone area fraction was lower in the epiphysis and tended to be lower (P &lt; 0.1) in the metaphysis in ob/ob mice compared to WT mice. Cartilage area fraction also decreased with age in the femoral epiphysis (Figure 1B) and metaphysis (Figure 1D), irrespective of genotype. Cartilage area fraction was higher in ob/ob compared to WT mice at both sites. Negligible levels of cartilage matrix were observed in the diaphysis of WT mice (Figure 1E). In contrast, cartilage matrix was present in the diaphysis of ob/ob mice and significant changes with age were not detected.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13664</offset><text>Photomicrographs illustrating the distribution of cartilage matrix in the femoral epiphysis, metaphysis, and diaphysis in representative 4-month-old WT and ob/ob mice are shown in Figure 2. By 4 months of age, little cartilage remained in femur epiphysis, metaphysis, or diaphysis in WT mice. In contrast, cartilage is clearly evident at all 3 sites in ob/ob mice. Bone bridging across the growth plate, indicative of cessation of longitudinal growth, was evident in 6-month-old WT and ob/ob mice (Figure 3) but not in 2-month-old or 4-month-old mice, verifying cessation of linear growth by 6 months of age in both genotypes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14291</offset><text>Study 2: Effect of Hypothalamic Leptin Gene Therapy on Bone and Cartilage in ob/ob Mice</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14379</offset><text>The effects of long-duration hypothalamic leptin gene therapy on cancellous bone area fraction in the femoral epiphysis and metaphysis and cartilage retention in the femoral epiphysis, metaphysis, and diaphysis in ob/ob mice are shown in Figure 4. There was a tendency (P &lt; 0.1) for cancellous bone area fraction to be higher in the epiphysis of rAAV-Lep-treated mice compared to untreated and rAAV-GFP-treated control mice (Figure 4A). Differences in cancellous bone area fraction were not detected with treatment in the femoral metaphysis (Figure 4C). Cartilage matrix was present in the epiphysis (Figure 4B), metaphysis (Figure 4D), and diaphysis (Figure 4E) in untreated and rAAV-GFP-treated control mice. Treatment with rAAV-Lep resulted in lower cartilage area fraction in the epiphysis, metaphysis, and diaphysis in comparison to untreated mice, lower cartilage area fraction in the metaphysis in comparison to rAAV-GFP mice and a tendency (P &lt; 0.1) for lower cartilage area fraction in the epiphysis and diaphysis in comparison to rAAV-GFP mice. Significant differences between untreated and rAAV-GFP-treated mice were not detected for any of the endpoints evaluated. Photomicrographs illustrating the distribution of cartilage matrix in representative 9-month-old untreated, rAAV-GFP-treated, and rAAV-Lep-treated ob/ob mice are shown in Figure 5.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15737</offset><text>The effects of long-duration hypothalamic leptin gene therapy on cellular indices of cancellous bone turnover in the femoral epiphysis are shown in Figure 6. Osteoclast perimeter (Figure 6A) and osteoblast perimeter (Figure 6B) were higher in rAAV-Lep-treated mice compared to untreated and rAAV-GFP-treated mice. Significant differences in either osteoclast perimeter or osteoblast perimeter were not detected between untreated and rAAV-GFP-treated controls.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>16197</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16208</offset><text>Compared to WT mice, more extracellular cartilage matrix was present in cancellous compartments (metaphysis and epiphysis) of distal femur in ob/ob mice. Cartilage matrix decreased with increasing age in both WT and ob/ob mice but, in marked contrast to WT mice, cartilage continued to be present in the epiphysis and metaphysis in skeletally mature 6-month-old ob/ob mice. Minimal or no cartilage matrix was found in the diaphysis of WT mice. In contrast, cartilage matrix was present in the diaphysis in ob/ob mice, but unlike at cancellous sites, did not decrease with age. Long-duration hypothalamic leptin gene therapy in growing ob/ob mice reduced cartilage matrix at all skeletal sites evaluated. Lack of differences between rAAV-Lep and rAAV-GFP-treated mice provides strong evidence that increased leptin levels and not differences arising from the application of gene therapy were responsible for the skeletal changes observed. At the cellular level, the reduction in cartilage in the epiphysis in rAAV-Lep-treated ob/ob mice was associated with increased bone turnover (increased osteoblast and osteoclast perimeters).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17338</offset><text>Bone resorption is reduced in leptin-deficient ob/ob mice and leptin receptor-deficient db/db mice due to impaired osteoclast function. Bone formation is also reduced in leptin-signaling-deficient mice due to reduced osteoblast-lined bone perimeter and reduced osteoblast activity. We hypothesized that the resulting reduction in turnover of primary spongiosa was the primary cause for prolonged retention of cartilage within the skeleton in ob/ob mice. This hypothesis is supported by the current study. The slower matrix turnover in the epiphysis compared to metaphysis was positively associated with longer retention of cartilage matrix. In addition, a reduction in cartilage in the epiphysis following hypothalamic leptin gene therapy was associated with increased bone turnover. A similar relationship was previously observed for the metaphysis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18189</offset><text>Osteoclasts play a key role in endochondral ossification. Osteoclasts are essential for (1) generation of primary spongiosa by directing vascular invasion into the growth plate and (2) replacement of mineralized cartilage matrix by bone to form secondary spongiosa. Cartilage matrix is prevalent in distal femur in 2-month-old WT mice because the rate of cartilage matrix deposition during longitudinal growth exceeds the capacity of matrix turnover to replace cartilage with bone. However, longitudinal bone growth slows with age and in male B6 mice ceases between 4 and 6 months of age. Cessation of linear bone growth in small rodents is due to the formation of bony bridges across growth plate cartilage precluding further elongation. In the current study, bony bridges were observed in the distal femur growth plate at 6 months of age in WT as well as ob/ob mice. The age range for longitudinal growth cessation corresponds to the disappearance of cartilage matrix from cancellous compartments.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19189</offset><text>Endochondral ossification is disrupted in long bones of ob/ob mice, resulting in shorter bones, abnormal cancellous architecture, and delayed replacement of cartilage matrix in primary spongiosa by bone matrix. In concordance with Kishida et al., we noted disorganized growth plate architecture in the leptin-deficient mice. Furthermore, prior studies demonstrated that thinning of the proliferative zone of the growth plate is associated with reduced longitudinal bone growth rate. Chondrocytes express the leptin receptor and leptin was shown to exert positive actions affecting growth plate organization and growth plate expansion. Hypertrophic chondrocytes contribute to programed removal of cartilage matrix by secretion of factors such as TNFSF11 (RANKL), MMP9 (matrix metallopeptidase 9), MMP13 (collagenase 3), and HMGB1 (high-mobility group protein 1) that mediate vascular invasion and are altered by leptin status. Thus, impaired chondrocyte function may contribute to the defect in osteoclast activity in ob/ob mice.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20218</offset><text>Cortical bone in the femoral diaphysis develops by secondary intramembranous ossification. The presence of cartilage within the diaphysis of ob/ob mice represents a pathological condition likely contributing to the lower biomechanical strength reported in ob/ob and db/db mice. Haversian (intracortical) bone remodeling is absent in mice. This may explain why cartilage matrix trapped in the distal femur diaphysis in ob/ob mice did not decline in quantity as the mice aged.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20693</offset><text>Leptin deficiency results in hypogonadism, hyperphagia, insulin resistance, and morbid obesity. These metabolic and endocrine abnormalities could indirectly influence bone metabolism and thus contribute to skeletal defects observed in ob/ob mice. Indeed, normalization of food intake, weight gain, and blood glucose levels in ob/ob mice actually exaggerated the abnormal skeletal phenotype, while estrogen receptor blockade did not impair the skeletal response of ob/ob mice to leptin. Additionally, leptin exerted actions on the skeleton at levels having minimal impact on either energy metabolism or gonadal function. Taken together, these findings provide strong evidence that leptin acts on the skeleton to regulate bone growth and turnover.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21439</offset><text>Leptin deficiency also results in hypocalcemia, retinopathy, hearing loss, and tooth defects. These abnormalities may be due, at least in part, to reduced osteoclast function. In support, defective bone resorption associated with osteopetrosis was shown to lead to impaired tooth eruption, and impaired hearing and vision.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21762</offset><text>Hypothalamic leptin gene therapy normalized bone microarchitecture in growing ob/ob mice by increasing bone growth and turnover. In the current study, hypothalamic leptin gene therapy promoted maturation of cancellous bone in distal femur. Infusion of leptin into the hypothalamus was initially reported to be antiosteogenic but subsequent studies failed to confirm this finding. Specifically, the latter studies reported that leptin infusion into the hypothalamus of ob/ob mice increased bone formation, bone mineral density, and expression of osteogenic genes. In support, we observed that increasing hypothalamic leptin levels by gene therapy increased histomorphometric, biochemical, and gene expression markers of bone formation in ob/ob mice. In addition to increased bone formation, hypothalamic leptin gene therapy increased osteoclast perimeter, an index of bone resorption, suggesting that leptin regulates bone turnover as well as bone accrual.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22718</offset><text>In summary, whereas cartilage matrix was absent within bone in 6-month-old WT mice, ob/ob mice retained cartilage matrix to varying degrees at all anatomical sites evaluated. Long-duration hypothalamic rAAV-Lep gene therapy in ob/ob mice increased bone turnover, resulting in substantial reduction in cartilage matrix within bone. Our findings (1) support the concept that leptin is important for normal replacement of cartilage by bone, and (2) demonstrate that osteopetrosis in ob/ob mice is site-specific and reversible by leptin at skeletal sites capable of undergoing robust bone turnover.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">footnote</infon><offset>23313</offset><text>Declaration of interest: The authors have nothing to disclose.</text></passage><passage><infon key="fpage">657</infon><infon key="lpage">662</infon><infon key="name_0">surname:Arruda;given-names:M</infon><infon key="name_1">surname:Coelho;given-names:MC</infon><infon key="name_2">surname:Moraes;given-names:AB</infon><infon key="name_3">surname:de Paula Paranhos-Neto;given-names:F</infon><infon key="name_4">surname:Madeira;given-names:M</infon><infon key="name_5">surname:Farias;given-names:ML</infon><infon key="name_6">surname:Vieira Neto;given-names:L</infon><infon key="pub-id_pmid">26387875</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2016</infon><offset>23376</offset><text>Bone Mineral Density and Microarchitecture in Patients With Autosomal Dominant Osteopetrosis: A Report of Two Cases</text></passage><passage><infon key="fpage">1710</infon><infon key="lpage">1720</infon><infon key="name_0">surname:Bartell;given-names:SM</infon><infon key="name_1">surname:Rayalam;given-names:S</infon><infon key="name_2">surname:Ambati;given-names:S</infon><infon key="name_3">surname:Gaddam;given-names:DR</infon><infon key="name_4">surname:Hartzell;given-names:DL</infon><infon key="name_5">surname:Hamrick;given-names:M</infon><infon key="name_6">surname:She;given-names:JX</infon><infon key="name_7">surname:Della-Fera;given-names:MA</infon><infon key="name_8">surname:Baile;given-names:CA</infon><infon key="pub-id_pmid">21520275</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2011</infon><offset>23492</offset><text>Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice</text></passage><passage><infon key="fpage">457</infon><infon key="lpage">462</infon><infon key="name_0">surname:Batt;given-names:RA</infon><infon key="pub-id_pmid">744683</infon><infon key="section_type">REF</infon><infon key="source">Int J Obes</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1978</infon><offset>23667</offset><text>Abnormal dentition and decrease in body weight in the genetically obese mouse (genotype, ob/ob)</text></passage><passage><infon key="fpage">29</infon><infon key="lpage">34</infon><infon key="name_0">surname:Batt;given-names:RA</infon><infon key="pub-id_pmid">1314241</infon><infon key="section_type">REF</infon><infon key="source">Int J Obes Relat Metab Disord</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1992</infon><offset>23763</offset><text>Abnormal incisor teeth and body weight in the obese mouse (genotype ob/ob)</text></passage><passage><infon key="fpage">289</infon><infon key="lpage">300</infon><infon key="name_0">surname:Benjamini;given-names:Y</infon><infon key="name_1">surname:Hochberg;given-names:Y</infon><infon key="section_type">REF</infon><infon key="source">J Royal Statistical Society Series B</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">1995</infon><offset>23838</offset><text>Controlling the false discovery rate: a practical and powerful approach to multiple testing</text></passage><passage><infon key="fpage">189</infon><infon key="lpage">198</infon><infon key="name_0">surname:Beretta;given-names:E</infon><infon key="name_1">surname:Dube;given-names:MG</infon><infon key="name_2">surname:Kalra;given-names:PS</infon><infon key="name_3">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">12149495</infon><infon key="section_type">REF</infon><infon key="source">Pediatr Res</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">2002</infon><offset>23930</offset><text>Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: effects on serum ghrelin and appetite-regulating genes</text></passage><passage><infon key="fpage">3245</infon><infon key="lpage">3254</infon><infon key="name_0">surname:Boghossian;given-names:S</infon><infon key="name_1">surname:Dube;given-names:MG</infon><infon key="name_2">surname:Torto;given-names:R</infon><infon key="name_3">surname:Kalra;given-names:PS</infon><infon key="name_4">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">16962683</infon><infon key="section_type">REF</infon><infon key="source">Peptides</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2006</infon><offset>24104</offset><text>Hypothalamic clamp on insulin release by leptin-transgene expression</text></passage><passage><infon key="fpage">1594</infon><infon key="lpage">1604</infon><infon key="name_0">surname:Boghossian;given-names:S</infon><infon key="name_1">surname:Ueno;given-names:N</infon><infon key="name_2">surname:Dube;given-names:MG</infon><infon key="name_3">surname:Kalra;given-names:P</infon><infon key="name_4">surname:Kalra;given-names:S</infon><infon key="pub-id_pmid">17011078</infon><infon key="section_type">REF</infon><infon key="source">Neurobiol Aging</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2007</infon><offset>24173</offset><text>Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin</text></passage><passage><infon key="fpage">707</infon><infon key="lpage">715</infon><infon key="name_0">surname:Cielinski;given-names:MJ</infon><infon key="name_1">surname:Marks;given-names:SC;suffix:Jr</infon><infon key="pub-id_pmid">7873301</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">1994</infon><offset>24301</offset><text>Neonatal reductions in osteoclast number and function account for the transient nature of osteopetrosis in the rat mutation microphthalmia blanc (mib)</text></passage><passage><infon key="fpage">292</infon><infon key="lpage">295</infon><infon key="name_0">surname:Considine;given-names:RV</infon><infon key="name_1">surname:Sinha;given-names:MK</infon><infon key="name_2">surname:Heiman;given-names:ML</infon><infon key="name_3">surname:Kriauciunas;given-names:A</infon><infon key="name_4">surname:Stephens;given-names:TW</infon><infon key="name_5">surname:Nyce;given-names:MR</infon><infon key="name_6">surname:Ohannesian;given-names:JP</infon><infon key="name_7">surname:Marco;given-names:CC</infon><infon key="name_8">surname:McKee;given-names:LJ</infon><infon key="name_9">surname:Bauer;given-names:TL</infon><infon key="pub-id_pmid">8532024</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">334</infon><infon key="year">1996</infon><offset>24452</offset><text>Serum immunoreactive-leptin concentrations in normal-weight and obese humans</text></passage><passage><infon key="fpage">19</infon><infon key="lpage">29</infon><infon key="name_0">surname:Del Fattore;given-names:A</infon><infon key="name_1">surname:Cappariello;given-names:A</infon><infon key="name_2">surname:Teti;given-names:A</infon><infon key="pub-id_pmid">17936098</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2008</infon><offset>24529</offset><text>Genetics, pathogenesis and complications of osteopetrosis</text></passage><passage><infon key="fpage">2</infon><infon key="lpage">17</infon><infon key="name_0">surname:Dempster;given-names:DW</infon><infon key="name_1">surname:Compston;given-names:JE</infon><infon key="name_2">surname:Drezner;given-names:MK</infon><infon key="name_3">surname:Glorieux;given-names:FH</infon><infon key="name_4">surname:Kanis;given-names:JA</infon><infon key="name_5">surname:Malluche;given-names:H</infon><infon key="name_6">surname:Meunier;given-names:PJ</infon><infon key="name_7">surname:Ott;given-names:SM</infon><infon key="name_8">surname:Recker;given-names:RR</infon><infon key="name_9">surname:Parfitt;given-names:AM</infon><infon key="pub-id_pmid">23197339</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2013</infon><offset>24587</offset><text>Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee</text></passage><passage><infon key="fpage">197</infon><infon key="lpage">207</infon><infon key="name_0">surname:Ducy;given-names:P</infon><infon key="name_1">surname:Amling;given-names:M</infon><infon key="name_2">surname:Takeda;given-names:S</infon><infon key="name_3">surname:Priemel;given-names:M</infon><infon key="name_4">surname:Schilling;given-names:AF</infon><infon key="name_5">surname:Beil;given-names:FT</infon><infon key="name_6">surname:Shen;given-names:J</infon><infon key="name_7">surname:Vinson;given-names:C</infon><infon key="name_8">surname:Rueger;given-names:JM</infon><infon key="name_9">surname:Karsenty;given-names:G</infon><infon key="pub-id_pmid">10660043</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2000</infon><offset>24741</offset><text>Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass</text></passage><passage><infon key="fpage">9</infon><infon key="lpage">13</infon><infon key="name_0">surname:Ealey;given-names:KN</infon><infon key="name_1">surname:Fonseca;given-names:D</infon><infon key="name_2">surname:Archer;given-names:MC</infon><infon key="name_3">surname:Ward;given-names:WE</infon><infon key="pub-id_pmid">16764953</infon><infon key="section_type">REF</infon><infon key="source">Regul Pept</infon><infon key="type">ref</infon><infon key="volume">136</infon><infon key="year">2006</infon><offset>24833</offset><text>Bone abnormalities in adolescent leptin-deficient mice</text></passage><passage><infon key="fpage">343</infon><infon key="lpage">350</infon><infon key="name_0">surname:Gat-Yablonski;given-names:G</infon><infon key="name_1">surname:Ben-Ari;given-names:T</infon><infon key="name_2">surname:Shtaif;given-names:B</infon><infon key="name_3">surname:Potievsky;given-names:O</infon><infon key="name_4">surname:Moran;given-names:O</infon><infon key="name_5">surname:Eshet;given-names:R</infon><infon key="name_6">surname:Maor;given-names:G</infon><infon key="name_7">surname:Segev;given-names:Y</infon><infon key="name_8">surname:Phillip;given-names:M</infon><infon key="pub-id_pmid">14525912</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">145</infon><infon key="year">2004</infon><offset>24888</offset><text>Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth</text></passage><passage><infon key="fpage">1197</infon><infon key="lpage">1207</infon><infon key="name_0">surname:Glatt;given-names:V</infon><infon key="name_1">surname:Canalis;given-names:E</infon><infon key="name_2">surname:Stadmeyer;given-names:L</infon><infon key="name_3">surname:Bouxsein;given-names:ML</infon><infon key="pub-id_pmid">17488199</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2007</infon><offset>24972</offset><text>Age-related changes in trabecular architecture differ in female and male C57BL/6J mice</text></passage><passage><infon key="fpage">1607</infon><infon key="lpage">1611</infon><infon key="name_0">surname:Hamrick;given-names:MW</infon><infon key="pub-id_pmid">15355554</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2004</infon><offset>25059</offset><text>Leptin, bone mass, and the thrifty phenotype</text></passage><passage><infon key="fpage">994</infon><infon key="lpage">1001</infon><infon key="name_0">surname:Hamrick;given-names:MW</infon><infon key="name_1">surname:Della-Fera;given-names:MA</infon><infon key="name_2">surname:Choi;given-names:YH</infon><infon key="name_3">surname:Pennington;given-names:C</infon><infon key="name_4">surname:Hartzell;given-names:D</infon><infon key="name_5">surname:Baile;given-names:CA</infon><infon key="pub-id_pmid">15883640</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2005</infon><offset>25104</offset><text>Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice</text></passage><passage><infon key="fpage">376</infon><infon key="lpage">383</infon><infon key="name_0">surname:Hamrick;given-names:MW</infon><infon key="name_1">surname:Pennington;given-names:C</infon><infon key="name_2">surname:Newton;given-names:D</infon><infon key="name_3">surname:Xie;given-names:D</infon><infon key="name_4">surname:Isales;given-names:C</infon><infon key="pub-id_pmid">15003785</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2004</infon><offset>25220</offset><text>Leptin deficiency produces contrasting phenotypes in bones of the limb and spine</text></passage><passage><infon key="fpage">e27482</infon><infon key="name_0">surname:Henriksen;given-names:K</infon><infon key="name_1">surname:Flores;given-names:C</infon><infon key="name_2">surname:Thomsen;given-names:JS</infon><infon key="name_3">surname:Bruel;given-names:AM</infon><infon key="name_4">surname:Thudium;given-names:CS</infon><infon key="name_5">surname:Neutzsky-Wulff;given-names:AV</infon><infon key="name_6">surname:Langenbach;given-names:GE</infon><infon key="name_7">surname:Sims;given-names:N</infon><infon key="name_8">surname:Askmyr;given-names:M</infon><infon key="name_9">surname:Martin;given-names:TJ</infon><infon key="pub-id_pmid">22087326</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2011</infon><offset>25301</offset><text>Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength</text></passage><passage><infon key="fpage">214</infon><infon key="lpage">223</infon><infon key="name_0">surname:Hoshi;given-names:K</infon><infon key="name_1">surname:Ogata;given-names:N</infon><infon key="name_2">surname:Shimoaka;given-names:T</infon><infon key="name_3">surname:Terauchi;given-names:Y</infon><infon key="name_4">surname:Kadowaki;given-names:T</infon><infon key="name_5">surname:Kenmotsu;given-names:S</infon><infon key="name_6">surname:Chung;given-names:UI</infon><infon key="name_7">surname:Ozawa;given-names:H</infon><infon key="name_8">surname:Nakamura;given-names:K</infon><infon key="name_9">surname:Kawaguchi;given-names:H</infon><infon key="pub-id_pmid">14969391</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2004</infon><offset>25445</offset><text>Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage</text></passage><passage><infon key="fpage">2436</infon><infon key="lpage">2443</infon><infon key="name_0">surname:Ishida;given-names:H</infon><infon key="name_1">surname:Cunningham;given-names:NS</infon><infon key="name_2">surname:Henry;given-names:HL</infon><infon key="name_3">surname:Norman;given-names:AW</infon><infon key="pub-id_pmid">2836163</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">122</infon><infon key="year">1988</infon><offset>25558</offset><text>The number of 1,25-dihydroxyvitamin D3 receptors is decreased in both intestine and kidney of genetically diabetic db/db mice</text></passage><passage><infon key="fpage">1012</infon><infon key="lpage">1019</infon><infon key="name_0">surname:Iwaniec;given-names:UT</infon><infon key="name_1">surname:Boghossian;given-names:S</infon><infon key="name_2">surname:Lapke;given-names:PD</infon><infon key="name_3">surname:Turner;given-names:RT</infon><infon key="name_4">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">17346852</infon><infon key="section_type">REF</infon><infon key="source">Peptides</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2007</infon><offset>25684</offset><text>Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice</text></passage><passage><infon key="fpage">404</infon><infon key="lpage">412</infon><infon key="name_0">surname:Iwaniec;given-names:UT</infon><infon key="name_1">surname:Dube;given-names:MG</infon><infon key="name_2">surname:Boghossian;given-names:S</infon><infon key="name_3">surname:Song;given-names:H</infon><infon key="name_4">surname:Helferich;given-names:WG</infon><infon key="name_5">surname:Turner;given-names:RT</infon><infon key="name_6">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">19095090</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2009</infon><offset>25775</offset><text>Body mass influences cortical bone mass independent of leptin signaling</text></passage><passage><infon key="fpage">325</infon><infon key="lpage">341</infon><infon key="name_0">surname:Iwaniec;given-names:UT</infon><infon key="name_1">surname:Wronski;given-names:TJ</infon><infon key="name_2">surname:Turner;given-names:RT</infon><infon key="pub-id_pmid">18369927</infon><infon key="section_type">REF</infon><infon key="source">Methods Mol Biol</infon><infon key="type">ref</infon><infon key="volume">447</infon><infon key="year">2008</infon><offset>25847</offset><text>Histological analysis of bone</text></passage><passage><infon key="fpage">967</infon><infon key="lpage">973</infon><infon key="name_0">surname:Kalra;given-names:SP</infon><infon key="name_1">surname:Dube;given-names:MG</infon><infon key="name_2">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">19428775</infon><infon key="section_type">REF</infon><infon key="source">Peptides</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2009</infon><offset>25877</offset><text>Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay</text></passage><passage><infon key="fpage">607</infon><infon key="lpage">621</infon><infon key="name_0">surname:Kishida;given-names:Y</infon><infon key="name_1">surname:Hirao;given-names:M</infon><infon key="name_2">surname:Tamai;given-names:N</infon><infon key="name_3">surname:Nampei;given-names:A</infon><infon key="name_4">surname:Fujimoto;given-names:T</infon><infon key="name_5">surname:Nakase;given-names:T</infon><infon key="name_6">surname:Shimizu;given-names:N</infon><infon key="name_7">surname:Yoshikawa;given-names:H</infon><infon key="name_8">surname:Myoui;given-names:A</infon><infon key="pub-id_pmid">16039170</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2005</infon><offset>25963</offset><text>Leptin regulates chondrocyte differentiation and matrix maturation during endochondral ossification</text></passage><passage><infon key="name_0">surname:Kocher;given-names:MS</infon><infon key="name_1">surname:Kasser;given-names:JR</infon><infon key="section_type">REF</infon><infon key="source">Am J Orthop</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2003</infon><offset>26063</offset><text>Osteopetrosis</text></passage><passage><infon key="fpage">37997</infon><infon key="lpage">38006</infon><infon key="name_0">surname:Kondo;given-names:T</infon><infon key="name_1">surname:Kahn;given-names:CR</infon><infon key="pub-id_pmid">15201286</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="year">2004</infon><offset>26077</offset><text>Altered insulin signaling in retinal tissue in diabetic states</text></passage><passage><infon key="fpage">57</infon><infon key="lpage">64</infon><infon key="name_0">surname:Koskinen;given-names:A</infon><infon key="name_1">surname:Vuolteenaho;given-names:K</infon><infon key="name_2">surname:Nieminen;given-names:R</infon><infon key="name_3">surname:Moilanen;given-names:T</infon><infon key="name_4">surname:Moilanen;given-names:E</infon><infon key="pub-id_pmid">21345293</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Rheumatol</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2011</infon><offset>26140</offset><text>Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients</text></passage><passage><infon key="fpage">211</infon><infon key="lpage">216</infon><infon key="name_0">surname:Lee;given-names:HS</infon><infon key="name_1">surname:Kim;given-names:KR</infon><infon key="name_2">surname:Chung;given-names:WH</infon><infon key="name_3">surname:Cho;given-names:YS</infon><infon key="name_4">surname:Hong;given-names:SH</infon><infon key="pub-id_pmid">19434270</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Otorhinolaryngol</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2008</infon><offset>26296</offset><text>Early sensorineural hearing loss in ob/ob mouse, an animal model of type 2 diabetes</text></passage><passage><infon key="fpage">110</infon><infon key="name_0">surname:Lindenmaier;given-names:LB</infon><infon key="name_1">surname:Philbrick;given-names:KA</infon><infon key="name_2">surname:Branscum;given-names:AJ</infon><infon key="name_3">surname:Kalra;given-names:SP</infon><infon key="name_4">surname:Turner;given-names:RT</infon><infon key="name_5">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">27579023</infon><infon key="section_type">REF</infon><infon key="source">Front Endocrinol (Lausanne)</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>26380</offset><text>Hypothalamic leptin gene therapy reduces bone marrow adiposity in ob/ob mice fed regular and high-fat diets</text></passage><passage><infon key="fpage">109</infon><infon key="lpage">121</infon><infon key="name_0">surname:Mackie;given-names:EJ</infon><infon key="name_1">surname:Tatarczuch;given-names:L</infon><infon key="name_2">surname:Mirams;given-names:M</infon><infon key="pub-id_pmid">21642379</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">211</infon><infon key="year">2011</infon><offset>26488</offset><text>The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification</text></passage><passage><infon key="fpage">261</infon><infon key="lpage">267</infon><infon key="name_0">surname:Martin;given-names:EA</infon><infon key="name_1">surname:Ritman;given-names:EL</infon><infon key="name_2">surname:Turner;given-names:RT</infon><infon key="pub-id_pmid">12667553</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2003</infon><offset>26595</offset><text>Time course of epiphyseal growth plate fusion in rat tibiae</text></passage><passage><infon key="fpage">161</infon><infon key="lpage">174</infon><infon key="name_0">surname:Odgren;given-names:PR</infon><infon key="name_1">surname:Witwicka;given-names:H</infon><infon key="name_2">surname:Reyes-Gutierrez;given-names:P</infon><infon key="pub-id_pmid">26818783</infon><infon key="section_type">REF</infon><infon key="source">Connect Tissue Res</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2016</infon><offset>26655</offset><text>The cast of clasts: catabolism and vascular invasion during bone growth, repair, and disease by osteoclasts, chondroclasts, and septoclasts</text></passage><passage><infon key="fpage">3686</infon><infon key="lpage">3695</infon><infon key="name_0">surname:Ozata;given-names:M</infon><infon key="name_1">surname:Ozdemir;given-names:IC</infon><infon key="name_2">surname:Licinio;given-names:J</infon><infon key="pub-id_pmid">10523015</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">1999</infon><offset>26795</offset><text>Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects</text></passage><passage><infon key="fpage">2018</infon><infon key="lpage">2029</infon><infon key="name_0">surname:Philbrick;given-names:KA</infon><infon key="name_1">surname:Turner;given-names:RT</infon><infon key="name_2">surname:Branscum;given-names:AJ</infon><infon key="name_3">surname:Wong;given-names:CP</infon><infon key="name_4">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">26370912</infon><infon key="section_type">REF</infon><infon key="source">Anat Rec (Hoboken)</infon><infon key="type">ref</infon><infon key="volume">298</infon><infon key="year">2015</infon><offset>27099</offset><text>Paradoxical effects of partial leptin deficiency on bone in growing female mice</text></passage><passage><infon key="fpage">461</infon><infon key="lpage">474</infon><infon key="name_0">surname:Philbrick;given-names:KA</infon><infon key="name_1">surname:Wong;given-names:CP</infon><infon key="name_2">surname:Branscum;given-names:AJ</infon><infon key="name_3">surname:Turner;given-names:RT</infon><infon key="name_4">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">28057869</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">232</infon><infon key="year">2017</infon><offset>27179</offset><text>Leptin stimulates bone formation in ob/ob mice at doses having minimal impact on energy metabolism</text></passage><passage><infon key="fpage">170</infon><infon key="lpage">180</infon><infon key="name_0">surname:Schroeter;given-names:MR</infon><infon key="name_1">surname:Stein;given-names:S</infon><infon key="name_2">surname:Heida;given-names:NM</infon><infon key="name_3">surname:Leifheit-Nestler;given-names:M</infon><infon key="name_4">surname:Cheng;given-names:IF</infon><infon key="name_5">surname:Gogiraju;given-names:R</infon><infon key="name_6">surname:Christiansen;given-names:H</infon><infon key="name_7">surname:Maier;given-names:LS</infon><infon key="name_8">surname:Shah;given-names:AM</infon><infon key="name_9">surname:Hasenfuss;given-names:G</infon><infon key="pub-id_pmid">22065732</infon><infon key="section_type">REF</infon><infon key="source">Cardiovasc Res</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">2012</infon><offset>27278</offset><text>Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9</text></passage><passage><infon key="fpage">522</infon><infon key="lpage">536</infon><infon key="name_0">surname:Sobacchi;given-names:C</infon><infon key="name_1">surname:Schulz;given-names:A</infon><infon key="name_2">surname:Coxon;given-names:FP</infon><infon key="name_3">surname:Villa;given-names:A</infon><infon key="name_4">surname:Helfrich;given-names:MH</infon><infon key="pub-id_pmid">23877423</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Endocrinol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2013</infon><offset>27399</offset><text>Osteopetrosis: genetics, treatment and new insights into osteoclast function</text></passage><passage><infon key="fpage">73</infon><infon key="lpage">78</infon><infon key="name_0">surname:Steppan;given-names:CM</infon><infon key="name_1">surname:Crawford;given-names:DT</infon><infon key="name_2">surname:Chidsey-Frink;given-names:KL</infon><infon key="name_3">surname:Ke;given-names:H</infon><infon key="name_4">surname:Swick;given-names:AG</infon><infon key="pub-id_pmid">11024568</infon><infon key="section_type">REF</infon><infon key="source">Regul Pept</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">2000</infon><offset>27476</offset><text>Leptin is a potent stimulator of bone growth in ob/ob mice</text></passage><passage><infon key="fpage">129</infon><infon key="lpage">141</infon><infon key="name_0">surname:Turner;given-names:RT</infon><infon key="name_1">surname:Dube;given-names:M</infon><infon key="name_2">surname:Branscum;given-names:AJ</infon><infon key="name_3">surname:Wong;given-names:CP</infon><infon key="name_4">surname:Olson;given-names:DA</infon><infon key="name_5">surname:Zhong;given-names:X</infon><infon key="name_6">surname:Kweh;given-names:MF</infon><infon key="name_7">surname:Larkin;given-names:IV</infon><infon key="name_8">surname:Wronski;given-names:TJ</infon><infon key="name_9">surname:Rosen;given-names:CJ</infon><infon key="pub-id_pmid">26487675</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">227</infon><infon key="year">2015</infon><offset>27535</offset><text>Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss</text></passage><passage><infon key="fpage">22</infon><infon key="lpage">34</infon><infon key="name_0">surname:Turner;given-names:RT</infon><infon key="name_1">surname:Kalra;given-names:SP</infon><infon key="name_2">surname:Wong;given-names:CP</infon><infon key="name_3">surname:Philbrick;given-names:KA</infon><infon key="name_4">surname:Lindenmaier;given-names:LB</infon><infon key="name_5">surname:Boghossian;given-names:S</infon><infon key="name_6">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">22887758</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2013</infon><offset>27631</offset><text>Peripheral leptin regulates bone formation</text></passage><passage><infon key="fpage">357</infon><infon key="lpage">367</infon><infon key="name_0">surname:Turner;given-names:RT</infon><infon key="name_1">surname:Philbrick;given-names:KA</infon><infon key="name_2">surname:Kuah;given-names:AF</infon><infon key="name_3">surname:Branscum;given-names:AJ</infon><infon key="name_4">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">28428364</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">233</infon><infon key="year">2017</infon><offset>27674</offset><text>Role of estrogen receptor signaling in skeletal response to leptin in female ob/ob mice</text></passage><passage><infon key="fpage">M1</infon><infon key="lpage">15</infon><infon key="name_0">surname:Turner;given-names:RT</infon><infon key="name_1">surname:Philbrick;given-names:KA</infon><infon key="name_2">surname:Wong;given-names:CP</infon><infon key="name_3">surname:Olson;given-names:DA</infon><infon key="name_4">surname:Branscum;given-names:AJ</infon><infon key="name_5">surname:Iwaniec;given-names:UT</infon><infon key="pub-id_pmid">24990938</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">223</infon><infon key="year">2014</infon><offset>27762</offset><text>Morbid obesity attenuates the skeletal abnormalities associated with leptin deficiency in mice</text></passage><passage><infon key="fpage">1905</infon><infon key="lpage">1911</infon><infon key="name_0">surname:Tuukkanen;given-names:J</infon><infon key="name_1">surname:Koivukangas;given-names:A</infon><infon key="name_2">surname:Jamsa;given-names:T</infon><infon key="name_3">surname:Sundquist;given-names:K</infon><infon key="name_4">surname:Mackay;given-names:CA</infon><infon key="name_5">surname:Marks;given-names:SC;suffix:Jr</infon><infon key="pub-id_pmid">11028442</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2000</infon><offset>27857</offset><text>Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations</text></passage><passage><infon key="fpage">4176</infon><infon key="lpage">4184</infon><infon key="name_0">surname:Ueno;given-names:N</infon><infon key="name_1">surname:Dube;given-names:MG</infon><infon key="name_2">surname:Inui;given-names:A</infon><infon key="name_3">surname:Kalra;given-names:PS</infon><infon key="name_4">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">15155574</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">145</infon><infon key="year">2004</infon><offset>27952</offset><text>Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy</text></passage><passage><infon key="fpage">2332</infon><infon key="lpage">2342</infon><infon key="name_0">surname:Ueno;given-names:N</infon><infon key="name_1">surname:Inui;given-names:A</infon><infon key="name_2">surname:Kalra;given-names:PS</infon><infon key="name_3">surname:Kalra;given-names:SP</infon><infon key="pub-id_pmid">16621153</infon><infon key="section_type">REF</infon><infon key="source">Peptides</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2006</infon><offset>28127</offset><text>Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice</text></passage><passage><infon key="fpage">2194</infon><infon key="lpage">2206</infon><infon key="name_0">surname:Unnanuntana;given-names:A</infon><infon key="name_1">surname:Rebolledo;given-names:BJ</infon><infon key="name_2">surname:Khair;given-names:MM</infon><infon key="name_3">surname:DiCarlo;given-names:EF</infon><infon key="name_4">surname:Lane;given-names:JM</infon><infon key="pub-id_pmid">21107923</infon><infon key="section_type">REF</infon><infon key="source">Clin Orthop Relat Res</infon><infon key="type">ref</infon><infon key="volume">469</infon><infon key="year">2011</infon><offset>28284</offset><text>Diseases affecting bone quality: beyond osteoporosis</text></passage><passage><infon key="fpage">330</infon><infon key="lpage">336</infon><infon key="name_0">surname:Welch;given-names:BL</infon><infon key="section_type">REF</infon><infon key="source">Biometrika</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">1951</infon><offset>28337</offset><text>On the comparison of several mean values: an alternative approach</text></passage><passage><infon key="fpage">457</infon><infon key="lpage">463</infon><infon key="name_0">surname:Whyte;given-names:MP</infon><infon key="name_1">surname:Wenkert;given-names:D</infon><infon key="name_2">surname:Clements;given-names:KL</infon><infon key="name_3">surname:McAlister;given-names:WH</infon><infon key="name_4">surname:Mumm;given-names:S</infon><infon key="pub-id_pmid">12890844</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">349</infon><infon key="year">2003</infon><offset>28403</offset><text>Bisphosphonate-induced osteopetrosis</text></passage><passage><infon key="fpage">1698</infon><infon key="lpage">1709</infon><infon key="name_0">surname:Williams;given-names:GA</infon><infon key="name_1">surname:Callon;given-names:KE</infon><infon key="name_2">surname:Watson;given-names:M</infon><infon key="name_3">surname:Costa;given-names:JL</infon><infon key="name_4">surname:Ding;given-names:Y</infon><infon key="name_5">surname:Dickinson;given-names:M</infon><infon key="name_6">surname:Wang;given-names:Y</infon><infon key="name_7">surname:Naot;given-names:D</infon><infon key="name_8">surname:Reid;given-names:IR</infon><infon key="name_9">surname:Cornish;given-names:J</infon><infon key="pub-id_pmid">21328476</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2011</infon><offset>28440</offset><text>Skeletal phenotype of the leptin receptor-deficient db/db mouse</text></passage><passage><infon key="fpage">1235</infon><infon key="lpage">1241</infon><infon key="name_0">surname:Xiong;given-names:J</infon><infon key="name_1">surname:Onal;given-names:M</infon><infon key="name_2">surname:Jilka;given-names:RL</infon><infon key="name_3">surname:Weinstein;given-names:RS</infon><infon key="name_4">surname:Manolagas;given-names:SC</infon><infon key="name_5">surname:O’Brien;given-names:CA</infon><infon key="pub-id_pmid">21909103</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2011</infon><offset>28504</offset><text>Matrix-embedded cells control osteoclast formation</text></passage><passage><infon key="fpage">425</infon><infon key="lpage">432</infon><infon key="name_0">surname:Zhang;given-names:Y</infon><infon key="name_1">surname:Proenca;given-names:R</infon><infon key="name_2">surname:Maffei;given-names:M</infon><infon key="name_3">surname:Barone;given-names:M</infon><infon key="name_4">surname:Leopold;given-names:L</infon><infon key="name_5">surname:Friedman;given-names:JM</infon><infon key="pub-id_pmid">7984236</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">372</infon><infon key="year">1994</infon><offset>28555</offset><text>Positional cloning of the mouse obese gene and its human homologue</text></passage><passage><infon key="file">nihms925100f1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>28622</offset><text>Effects of age and genotype on cancellous bone area fraction in distal femur epiphysis (A) and metaphysis (C) and cartilage retention in cancellous bone in distal femur epiphysis (B) and metaphysis (D) and in cortical bone in femur diaphysis (E) in 2-month-old, 4-month-old, and 6-month-old male WT and leptin-deficient ob/ob mice. Data are mean ± SE; n = 10/group for 2-month-old mice, n = 5/group for 4-month-old mice, n = 3 and 5/group for 6-month-old WT and ob/ob mice, respectively.</text></passage><passage><infon key="file">nihms925100f2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>29111</offset><text>Photomicrographs of the distal femur epiphysis, metaphysis, and diaphysis in representative 4-month-old male WT mice (A, C, E) and 4-month-old male leptin-deficient ob/ob mice (B, D, F). Whereas cartilage matrix was rare in the epiphysis in WT mice (A), cartilage matrix and chondrocytes were readily visible in the epiphysis of ob/ob mice (B). Leptin-deficient ob/ob mice also exhibited a highly disorganized growth plate architecture, characterized by irregular margins and width (B). Cartilage was rare in the metaphysis and diaphysis of WT mice (C and E, respectively), but present at both sites in ob/ob mice (D and F).</text></passage><passage><infon key="file">nihms925100f3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>29736</offset><text>Photomicrographs of growth plate in distal femur in representative 6-month-old male WT (A) and 6-month-old male leptin-deficient ob/ob mouse (B). The bony bridges are indicative of cessation of longitudinal growth.</text></passage><passage><infon key="file">nihms925100f4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>29951</offset><text>Effects of long-duration (7 months) hypothalamic leptin gene therapy (rAAV-Lep) on cancellous bone area fraction in distal femur epiphysis (A) and metaphysis (C) and cartilage retention in cancellous bone in distal femur epiphysis (B) and metaphysis (D) and in cortical bone in femur diaphysis (E) in male ob/ob mice. Data are mean ± SE; n = 7-9/group, adifferent from untreated, P &lt; 0.05, a*P &lt; 0.1; bdifferent rAAV-GFP, P &lt; 0.05, b*P &lt; 0.1.</text></passage><passage><infon key="file">nihms925100f5.jpg</infon><infon key="id">F5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>30395</offset><text>Photomicrographs of the distal femur epiphysis (A, B, C), metaphysis (D, E, F), and diaphysis (G, H, I) in representative 9-month-old untreated, rAAV-GFP-treated and rAAV-Lep-treated male ob/ob mice at 7 months post-vector administration. Note the presence of cartilage matrix in epiphysis, metaphysis, and diaphysis of untreated mice (A, D, and G, respectively) and rAAV-GFP-treated mice (B, E, and H, respectively) and its absence in rAAV-Lep-treated mice (C, F, and I, respectively).</text></passage><passage><infon key="file">nihms925100f6.jpg</infon><infon key="id">F6</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>30882</offset><text>Effects of long-duration (7 months) hypothalamic leptin gene therapy on osteoclast perimeter (A) and osteoblast perimeter (B) in distal femur epiphysis in male ob/ob mice. Data are mean ± SE; n = 7-9/group. adifferent from untreated, P &lt; 0.05; bdifferent from rAAV-GFP, P &lt; 0.05.</text></passage></document>
</collection>